Theriva Biologics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TOVX NYSE American 2836 therivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Theriva Biologics, Inc.

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - Aug 11th, 2026 6:00 am
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - Aug 6th, 2026 6:00 am
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - Jul 7th, 2026 6:00 am
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research - Jun 11th, 2026 6:00 am
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - May 5th, 2026 2:30 pm
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - Apr 17th, 2026 2:05 pm
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma - Mar 23rd, 2026 6:00 am
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Mar 12th, 2026 6:00 am
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Feb 18th, 2026 6:00 am
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Feb 3rd, 2026 6:00 am
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design - Dec 30th, 2025 6:05 am
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - Dec 29th, 2025 6:00 am
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results - Nov 12th, 2025 6:00 am
Theriva Biologics Provides Response to Unusual Market Action - Oct 24th, 2025 12:31 pm